Aveva Drug Delivery Systems - Innovative Drug Delivery Solutions

Aveva Drug Delivery Systems is part of the $6.4 billion Nitto Denko company, one of the world's largest manufacturers of and a pioneer in transdermal drug delivery systems.

Nitto Denko has a 40-year history of providing pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfil unmet market needs or are high-quality, low-cost brand equivalents. Leveraging this experience, Aveva offers a full range of research, development and manufacturing capabilities using a number of sophisticated technologies to produce proprietary and generic transdermal drug delivery systems.

Drug delivery solutions

Aveva is committed to bringing innovative drug delivery solutions to the healthcare community through select industry partners. The fundamental aims of Aveva Drug Delivery Systems are much like the significant goals of Nitto Denko:

• Develop products friendly to the environment and people
• Help our industry partners improve the quality of life for patients by providing transdermal drug delivery systems for the prevention and treatment of disease

Vertical integration of adhesive, film coating, and transdermal formulation technology

Aveva Drug Delivery Systems owns proprietary transdermal thin and flexible formulation and manufacturing technologies. These technologies focus on elegant "matrix" patch designs that reliably adhere to the skin. These technologies can be optimised to suit particular drug characteristics and delivery needs, which can be rapidly developed from feasibility stage through clinical and commercial production stages. The company provides vertical integration of adhesive, film coating, and transdermal formulation technology to produce the most efficient and cost-effective products. Aveva is part of an international team of transdermal development scientists based in the US and Japan, that possess full development and commercial supply capabilities in the US and Japan.

Commercial successes can be found in the following therapeutic categories:

• Pain management
• Cardiovascular disease
• Asthma
• Women's Health
• Smoking Cessation
• Dermatologicals
• Nutraceuticals

Transdermal technology platforms are available for license, as well as proprietary adhesive and polymer formulations.

Technology Specialisations

Gel Matrix Adhesive System - At the forefront of innovation, Aveva and Nitto Denko offer the first and only marketed transdermal patch using a revolutionary gel matrix adhesive system for an unequaled balance of adhesion reliability and gentleness. The gel matrix adhesive is so gentle that it can be removed and reapplied.

Crystal Reservoir Technology - One of the most successful advancements in transdermal drug delivery systems, our crystal reservoir technology has resulted in smaller patches with a more controlled and sustained drug release. This technology is employed in the commercial production of the world's only Asthma patch, which is sold in Japan and is one of the most successful patches in the world.

Transdermal drug delivery systems

Our deal configurations are designed for maximum flexibility in accordance with the needs of our partners, and are as unique to each client as our customised transdermal drug delivery systems.

We offer:

• Global licensing opportunities for approved products and internal development projects
• Co-development
• Proprietary transdermal feasibility assessments for New Chemical Entities and mature brands

Contact

Aveva Drug Delivery Systems
3250 Commerce Parkway, Miramar
Florida 33025
US
Tel: + 1-954-430-3340
Fax: + 1-954-430-3390
www.avevadds.com

Contact person:
Robert J. Bloder, vice president business development
+ 1-954-624-1374
robert.bloder@avevadds.com